[Clinical experiences with carteolol in patients with essential hypertension].

Publications dealing with investigations made with 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) on patients with essential hypertension, are briefly reviewed. Four controlled studies are considered in greater depth. A comparative study with pindolol indicates that the beta-receptor blocker carteolol led to a significant reduction of the elevated blood pressure of patients with essential hypertension, as did pindolol. The antihypertensive effect of carteolol, however, was seen in a significantly higher number of patients than that of pindolol (p less than 0.05). A further controlled clinical study of carteolol, this time in comparison with diuretics, also demonstrated its satisfactory antihypertensive effect. It was found that carteolol displayed a significantly greater (p less than 0.05 and p less than 0.001) effectivity in reducing the blood pressure than did previously prescribed diuretics. In another test the antihypertensive effect was established by comparison with a placebo (p less than 0.001). Moreover, a study has been made of the effect of carteolol on the renin-aldosterone system. The results established that the hypotensive effect of carteolol is not associated with an inhibition of the renin-aldosterone system.